SEC Form 4 · accession 0001162194-16-000259
STANDARD BIOTOOLS INC. · LAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samuel D Colella
Director
Period of report
Nov 30, 2016
Accepted (ET)
Dec 2, 2016 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001162194
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2016 | G | 550 | $0.00 | D | 19,123 | D | |
| Common StockF2 | Nov 30, 2016 | P | 20,000 | $6.3235 | A | 39,123 | D | |
| Common StockF1 | holding | — | — | — | 5,561 | I | Colella Family Partners, L.P |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares are held by Colella Family Partners, L.P. ("Colella Partners"). The shares were received in in-kind distributions by Versant Ventures I, LLC, which is the general partner of each of Versant Venture Capital I, L.P., Versant Side Fund I, L.P., Versant Affiliates Fund I-A, L.P. and Versant Affiliates Fund I-B, L.P. (collectively, the "Versant Funds"), on November 4, 2013. The Reporting Person is the General Partner of Colella Partners. The Reporting Person disclaims beneficial ownership of such shares held by Colella Partners, except to the extent of his proportionate pecuniary interest therein, if any.
- F2The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $6.17 to $6.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.